Qiang Ma

Dr. Qiang Ma


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 January 2024 in Cells
Verified
Journal Article
Open access
PDF file
XWXiaolin Wang
Xiaolin Wang
CLCe Liang
Ce Liang
SWShimin Wang
Shimin Wang
QMQiang Ma
Qiang Ma
XPXiaojuan Pan
Xiaojuan Pan
BXBin Xiao
Bin Xiao
Gastric cancer (GC) is the most common type of malignant tumor within the gastrointestinal tract, and GC metastasis is associated with poor prognosis. Polypyrimidine tract binding protein 1 (PTBP1) is an RNA-binding protein implicated in various types of tumor development and metastasis. However, the role of PTBP1 in GC metastasis remains elusive. In this study, we verified that PTBP1 was upregulated in GC tissues and cell lines, and higher PTBP1 level was associated with poorer prognosis. It was shown that PTBP1 knockdown in vitro inhibited GC cell migration, whereas PTBP1 overexpression promoted the migration of GC cells. In vivo, the knockdown of PTBP1 notably reduced both the size and occurrence of metastatic nodules in a nude mice liver metastasis model. We identified phosphoglycerate kinase 1 (PGK1) as a downstream target of PTBP1 and found that PTBP1 increased the stability of PGK1 by directly binding to its mRNA. Furthermore, the PGK1/SNAIL axis could be required for PTBP1’s function in the promotion of GC cell migration. These discoveries suggest that PTBP1 could be a promising therapeutic target for GC.

22 February 2025 in Medical Oncology
Verified
Journal Article
Closed access
PDF file
CGChuanli Gao
Chuanli Gao
HYHui Yang
Hui Yang
JCJiao Cheng
Jiao Cheng
SHShuang He
Shuang He
YYYong Yang
Yong Yang
XZXiaowu Zhong
Xiaowu Zhong

26 February 2025 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
XLXiao Liu
Xiao Liu
JCJibing Cheng
Jibing Cheng
MTMaoju Tang
Maoju Tang
CLChongbo Liao
Chongbo Liao
YYYong Yang
Yong Yang
XGXiaolan Guo
Xiaolan Guo
Cyclobenzaprine hydrochloride (Flexeril) is a muscle relaxant primarily used to relieve muscle pain and spasms. However, its potential anti-cancer role remains largely unexplored. This study aims to investigate the inhibitory effect of Flexeril on esophageal squamous cell carcinoma (ESCC) and to uncover the molecular mechanisms through which it affects the proliferation and metastasis of ESCC. A compound library approved by the FDA was employed to screen drugs with inhibitory effects on ESCC. Cell viability was assessed using the Cell Counting Kit-8 (CCK-8) assay, and Plate colony formation was analyzed to evaluate the proliferative ability of ESCC cell lines (KYSE150 and Eca109) after treatment with Flexeril. Migratory ability was examined through Transwell and Scratch assays. Proteomics was performed to identify proteins regulated by Flexeril in KYSE150 and Eca109 cells. RT-PCR and Western blot were used to detect changes in related genes at the mRNA and protein levels after treatment with Flexeril. Drug affinity responsive target stability (DARTS) assay and cellular thermal shift assay (CETSA) were employed to identify the binding of Flexeril and JAK1 protein. Additionally, the comet assay was conducted to assess the DNA damage response in ESCC cells following WDHD1 knockdown or Flexeril exposure. Finally, tumor‑bearing nude mice model were constructed to evaluate the in vivo anticancer effects of Flexeril on ESCC. Flexeril significantly inhibited the proliferation and migration of ESCC cells in a time- and dose-dependent manner. Proteomics analysis identified WDHD1 as a downstream target of Flexeril exposure, and knockdown of WDHD1 mimicked the effects of Flexeril on proliferation and migration of ESCC. Conversely, overexpression of WDHD1 attenuated the inhibitory effects of Flexeril on ESCC. Mechanistically, the JAK1-STAT3 signaling pathway, but not the JAK2-STAT3 or PI3K-Akt-mTOR pathways, was involved in regulating WDHD1 expression in ESCC cells following Flexeril treatment. Overexpression of STAT3 or WDHD1 mitigated the inhibitory effects of Flexeril on ESCC proliferation and migration. Moreover, both Flexeril exposure and WDHD1 knockdown induced a DNA damage response (DDR) in ESCC cells. In addition, Flexeril significantly inhibited the growth of ESCC tumors in nude mice, downregulating the JAK1-STAT3-WDHD1 signaling pathway, with no significant damage observed in vital organs such as the heart, liver, spleen, lungs, or kidneys, as shown by histological examination. Flexeril exhibits anti-cancer effects in ESCC by inhibiting the JAK1-STAT3-WDHD1 axis and inducing DDR. These findings suggest that Flexeril may serve as a potential novel therapeutic agent for the treatment of ESCC.

26 November 2025 in Clinics
Verified
Journal Article
Open access
YZYu Zhou
Yu Zhou
LXLei Xu
Lei Xu
XZXiaowu Zhong
Xiaowu Zhong
XGXiaolan Guo
Xiaolan Guo
QMQiang Ma
Qiang Ma
Respiratory Tract Infections (RTIs) affect millions globally. This retrospective study evaluates routine hematological parameters for distinguishing bacterial from viral RTIs and develops a novel composite biomarker to enhance diagnostic efficiency, optimize treatment decisions, and improve patient outcomes. In the present study, 173 RTI cases (55 bacterial, 118 viral) were enrolled and classified by etiological diagnostic methods (Bacterial culture and identification, or PCR). In addition, 80 healthy controls were also enrolled. Data extraction included SAA, CRP, and blood routine parameters. Biomarkers were assessed individually or in combination using SPSS 26.0 (IBM Corp.) to identify optimal diagnostic models. Predominant pathogens included Gram-negative bacteria (Haemophilus influenzae, Klebsiella pneumoniae) and Gram-positive cocci (Streptococcus pneumoniae) for bacterial infections, and influenza A virus/SARS-CoV-2 for viral infections. Bacterial infections showed significantly elevated median levels versus viral infections, such as White Blood Cell (WBC) count is 8.96 vs. 6.22 × 109/L, Neutrophil (Neu) count is 6.69 vs. 4.55 × 109/L, Monocyte (Mon) count is 0.66 vs. 0.49 × 109/L, C-Reactive Protein (CRP) is 68.89 vs. 20.26 mg/L, Serum Amyloid A (SAA) is 280.75 vs. 81.16 mg/L. The performance analysis of differential diagnosis revealed that SAA is AUC = 0.693 (sensitivity 56.4 %, specificity 84.7 %), CRP is AUC = 0.686 (sensitivity 72.7 %, specificity 67.8 %), and Optimal composite (WBC + Neu + Mon + CRP) is AUC = 0.764 (sensitivity 75.2 %, specificity 89.3 %). The combination of biomarkers (WBC + Neu + Mon + CRP) demonstrates moderate ability (AUC = 0.764) in differentiating bacterial from viral RTIs, which plays a vital role in guiding clinical diagnosis and treatment.

24 February 2025 in Discover Oncology
Verified
Journal Article
Open access
PDF file
QMQiang Ma
Qiang Ma
WXWen Xu
Wen Xu
XGXiaolan Guo
Xiaolan Guo
Background Telomeric repeat binding factor 2 (TERF2), a key component of the Shelterin complex, is crucial for maintaining telomere integrity and genome stability. While the involvement of TERF2 in tumorigenesis and progression has been documented, comprehensive pan-cancer analyses of TERF2 across different malignancies remain scarce. Methods In the present study, the expression, mutations, immune cell infiltration, and interacting genes of TERF2 were systematically evaluated through bioinformatics analysis, and in vitro experiments were performed to elucidate the functional roles of TERF2 in gastric cancer. Results The findings revealed that TERF2 was predominantly upregulated in cholangiocarcinoma (CHOL), diffuse large B-cell lymphoma (DLBC), pancreatic adenocarcinoma (PAAD), stomach adenocarcinoma (STAD), and thymoma (THYM), correlating with tumor progression. Amplification and mutations were identified as the primary alterations of TERF2, particularly associated with liver hepatocellular carcinoma (LIHC). Furthermore, TERF2 expression was linked to the infiltration of cancer-associated fibroblasts and immune cells in certain cancer types. Protein–protein interaction (PPI) analysis highlighted several genes associated with TERF2, including CTCF, DDX19A, MATR3, ZFP1, and ZFP90. Additionally, in vitro experiments demonstrated that TERF2 knockdown significantly suppressed the proliferation and migration of gastric cancer cells. Conclusions These results suggest that dysregulation and mutations of TERF2 are prevalent across various cancers, contributing to tumor immunity and acting as an oncogenic factor, thus positioning TERF2 as a potential therapeutic target in cancer treatment.

23 March 2026 in Discover Oncology
Verified
Journal Article
Open access
PDF file
MYMiyuan Yang
Miyuan Yang
QZQuanneng Zhao
Quanneng Zhao
ZZZhihua Zuo
Zhihua Zuo
LXLei Xu
Lei Xu
XZXiaowu Zhong
Xiaowu Zhong
QMQiang Ma
Qiang Ma
Esophageal cancer (EC) is a malignant tumor characterized by high incidence and mortality, and its complex pathogenesis necessitates the development of effective therapeutic strategies. In this study, we investigated the anti-cancer effects and underlying mechanisms of Morusin against EC using network pharmacology, molecular dynamics (MD) simulation, and in vitro experiments. Transcriptomic analysis identified 3,540 differentially expressed genes in EC as potential therapeutic targets, while potential targets of Morusin were predicted using the SWISSprediction database. The intersection analysis revealed 21 common genes, which may represent the key targets of Morusin in EC treatment. A protein–protein interaction (PPI) network was constructed using the STRING database and analyzed in Cytoscape 3.8.0, identifying MAPK3, PTGS2, and HSP90AA1 as core hub genes. GO enrichment analysis indicated that the biological processes involved in Morusin’s anti-EC activity mainly included peptidyl-serine phosphorylation, peptidyl-serine modification, and aging. The cellular components were primarily associated with focal adhesion, cell–substrate junction, and caveola, while the molecular functions were enriched in protein serine kinase activity, protein serine/threonine kinase activity, protein serine/threonine/tyrosine kinase activity, and MAP kinase kinase activity. KEGG pathway enrichment suggested that Morusin may exert its effects through the HIF-1 signaling pathway, prostate cancer, and serotonergic synapse pathways. Molecular docking and MD simulations demonstrated stable binding of Morusin to ERK1 (MAPK3) and MEK1. In vitro assays revealed that 10 µM Morusin markedly inhibited the proliferation of EC cells (KYSE150 and TE1) without significant cytotoxicity toward normal esophageal epithelial cells (Het-1 A). Furthermore, Transwell and wound-healing assays confirmed that Morusin suppressed EC cell migration and invasion. Western blot analysis showed that Morusin treatment decreased Bcl-2 expression and increased cleaved-caspase3/caspase3, cleaved-PARP/PARP, and Bax levels, accompanied by significant downregulation of p-MEK1/2, p-MAPK3, and p-ERK2. Collectively, these findings suggest that Morusin inhibits proliferation, migration, and invasion, and induces apoptosis in EC cells by suppressing the MAPK signaling pathway.